We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pevonedistat is an enzyme inhibitor that leads to cancer cell death. Last year, the FDA granted it Breakthrough Therapy designation for patients with higher risk MDS. Read More
The multinational study will enroll approximately 1,332 participants who will get either 800 mg of molnupiravir or a placebo orally every 12 hours for five days. Read More
If the vaccine is approved, the shot is expected to be shipped worldwide via the World Health Organization-backed COVAX vaccine-sharing program. Read More
Astellas Pharma has stopped enrolling and dosing in a phase 1/2 clinical trial of its genetic therapy AT132 for X-linked myotubular myopathy, a rare neuromuscular disease, after a subject suffered a serious adverse event. Read More
Johnson & Johnson’s (J&J) vaccine technology that has been successful in its COVID-19 vaccine has not worked against human immunodeficiency virus (HIV), a more complex virus. Read More
CAR-T therapies make use of T-cells harvested from volunteers, which are then genetically altered to recognize cancer cells and inserted into patients to attack their tumors. Read More
Gantenerumab, Roche’s prime contender of Alzheimer disease drugs in the antiamyloid antibody space, has been around the block a few times in a series of failed phase 3 studies with the suffix “RoAD.” Read More
Novartis said its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah (tisagenlecleucel) failed to boost survival in patients with aggressive B-cell nonHodgkin lymphoma in a phase 3 study. Read More